Upadacitinib Shows Promising Results Against Severe Alopecia Areata
**The oral medication upadacitinib, approved for various forms of arthritis, showed positive results in phase 3 trials against severe alopecia areata. However, its use for this condition is still under regulatory review and is not approved for that indication.
- Phase 3 Trials: Two studies evaluated upadacitinib in adolescents and adults with severe alopecia areata.**
- Hair Results: In the disclosed data, between 35.2% and 45.8% of patients treated in one of the trials achieved at least 90% scalp coverage, depending on the dose received.**
- No Approval for This Indication: Although upadacitinib is approved for various inflammatory diseases, its use against alopecia areata remains under regulatory review.**
A Treatment Created for Another Disease
An oral medication originally developed to control inflammation associated with various forms of arthritis is being evaluated as a potential alternative for people with severe alopecia areata. This is upadacitinib, a daily administration pill that was studied in international clinical trials with participants who had lost a very high proportion of hair from the scalp.
Alopecia areata is not simply a cosmetic issue. It is an autoimmune disease in which the immune system mistakenly attacks hair follicles, causing hair loss that can appear in patches or extend to compromise the entire scalp, eyebrows, and even body hair.
In the most severe cases, the loss can affect personal confidence, social life, and mental health of those affected. The possibility of regaining a significant amount of hair has made JAK pathway inhibitors an area of interest for dermatological research.
The researchers' hypothesis is based on a biological connection between both diseases. If upadacitinib can reduce an excessive immune reaction related to arthritis, it could also slow the attack on hair follicles and allow hair to regrow in some people with alopecia areata.
What the International Trials Showed
The phase 3 trials recruited adolescents and adults with severe alopecia areata to evaluate the safety and efficacy of the drug under controlled conditions. In the materials associated with the clinical program, participants presented extensive hair loss from the scalp, a characteristic that allows studying the treatment in more severe cases.
Participants were randomly assigned to different groups to receive a daily dose of 15 mg of upadacitinib, a daily dose of 30 mg, or a placebo. This design allowed comparing the response of those who received the medication with the evolution of those who did not receive the active ingredient.
The disclosed results show signs of hair recovery after 24 weeks. In one of the trials, 35.2% of patients who received 15 mg and 45.8% of those who received 30 mg achieved at least 90% scalp coverage, measured using the SALT scale, according to results communicated by AbbVie.
Another report on the phase 3 program informed proportions of 36% and 47.1%, respectively, for the same hair coverage threshold. The differences between the reported percentages may correspond to different trials or result cuts, so they should not be combined as if they were a single rate.
These data describe results from clinical trials and do not mean that all treated individuals will regain hair or that the benefit will last indefinitely. It is also important to distinguish between scalp coverage and complete hair recovery: achieving at least 90% coverage does not necessarily equate to regaining 100% of lost hair.
A Possible Answer for an Unpredictable Disease
Alopecia areata can behave unpredictably, with losses limited to small areas or with a progression that removes hair from the scalp and other parts of the body. This variability makes it relevant to study the treatment in people with extensive involvement and prolonged periods without new growth.
The recovery observed after 24 weeks represents a hopeful sign for patients facing severe loss, but the available results do not allow establishing by themselves how long the benefit lasts, what happens after stopping treatment, or which patient profiles respond better.
Moreover, upadacitinib is still not approved for treating alopecia areata. Its safety and efficacy for this indication are under regulatory review in the United States and Europe. Therefore, the results of the trials should be interpreted as clinical evidence under evaluation and not as authorization for a new treatment.
For now, the main value of these trials lies in showing that a medication designed for inflammatory diseases may have potential application in an autoimmune condition affecting hair follicles. The research opens a pathway of hope for those facing severe loss, although regulatory review, long-term follow-up, and a more comprehensive assessment of risks and benefits are still pending.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

How Uniswap's Fee Switch Redefined Revenue

The Essence of Meme Harvesting in US Stocks Seen Through FAMI and JINQIAN

X Shifts Payment Method for U.S. Creators from Stripe to X Money

Three Public Chains Halt Operations in Four Days: Who Has the Power to Press the Pause Button?

HYPE First Adopted in US Cryptocurrency Index ETF, Following SOL

CLARITY Act could advance within weeks, Atkins says

Solana inflation cut is premature, SOL Strategies CEO says

What is Hedera Hashgraph and how does HBAR work?

Agentic Payment Research Report: From Payment Pathways to Ecological Landscape

What is Chainlink and how does the LINK oracle network work?

Crypto SEC News: 24/7 Trading on Wall Street with or without Blockchain?

From Glamsterdam to Hegotá: What Will Ethereum Address in Its Next Phase After Scaling?

Digital Asset Market Clarity Act: Can the Senate Crash Bitcoin by 25%?

Cardano clears key voting thresholds for constitutional committee renewal by 0.18% margin

SNDK Stock Trading Rewards: Share $100K on WEEX

NVDA, TSLA & AMD Trading Rewards: Share $100K on WEEX

How Much of the $1.5 Billion Can Be Recovered? The Realistic Boundaries and Industry Insights of Bybit's Lawsuit Against North Korea

Strikes on Iran: What Impact on Bitcoin, Stocks, Oil, and Gold?

Why is Grouping LP Better than PvP under Robinhood Chain's High Fees?

Bitcoin leads Ethereum and Solana in decentralization, ARK finds

NVIDIA, Tesla or AMD? 10 Stocks to Watch in WEEX Stock Spot 2.0

Can On-Chain Rollbacks Recover Stolen Assets?

South Korea's Cryptocurrency Market: Latest Guide for the Second Half of 2026

Solana's Nakamoto coefficient at 19, higher than Bitcoin and Ethereum

Important News from Last Night and This Morning (September 1 - September 2)

Strategy Opposes MSCI Index Exclusion Proposal

Guatemala Implements Anti-Money Laundering Control for Cryptocurrency Exchanges Starting September 2026

DEX vs CEX: Decentralized Exchanges Hit a Record

US PMI Falls in August: What This Means for Interest Rates and Investments












